SEK 0.01
(-3.23%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -232 Thousand SEK | 0.0% |
2022 | - SEK | -100.0% |
2021 | 798 Thousand SEK | 106727.31% |
2020 | 747.00 SEK | 0.0% |
2019 | - SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | -944 Thousand SEK | 0.0% |
2024 Q3 | - SEK | 100.0% |
2024 Q1 | - SEK | 100.0% |
2023 Q4 | -232 Thousand SEK | 0.0% |
2023 FY | -232 Thousand SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2022 Q1 | - SEK | -100.0% |
2022 FY | - SEK | -100.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2021 Q4 | 704 Thousand SEK | 0.0% |
2021 Q1 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2021 Q2 | - SEK | 0.0% |
2021 FY | 798 Thousand SEK | 106727.31% |
2020 Q4 | - SEK | 0.0% |
2020 FY | 747.00 SEK | 0.0% |
2019 FY | - SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AroCell AB (publ) | 6.07 Million SEK | 103.821% |
Devyser Diagnostics AB (publ) | 20.6 Million SEK | 101.126% |
Immunovia AB (publ) | 1.00 SEK | 23200100.0% |
Prostatype Genomics AB (publ) | 203 Thousand SEK | 214.286% |
SenzaGen AB | 6.22 Million SEK | 103.725% |